Analysts Expect Zynerba Pharmaceuticals Inc (ZYNE) to Post -$0.67 Earnings Per Share

Brokerages predict that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will report ($0.67) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Zynerba Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.73). Zynerba Pharmaceuticals reported earnings per share of ($0.60) in the same quarter last year, which would suggest a negative year-over-year growth rate of 11.7%. The firm is scheduled to announce its next earnings report on Monday, March 11th.

On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.87) per share for the current financial year, with EPS estimates ranging from ($2.94) to ($2.79). For the next year, analysts forecast that the company will post earnings of ($2.43) per share, with EPS estimates ranging from ($2.77) to ($1.84). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.23.

Several equities research analysts recently commented on the stock. Cantor Fitzgerald set a $21.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. HC Wainwright set a $23.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 13th. Finally, Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a research note on Saturday, November 17th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $17.75.

Several hedge funds and other institutional investors have recently modified their holdings of ZYNE. Millennium Management LLC bought a new position in shares of Zynerba Pharmaceuticals in the first quarter worth approximately $903,000. Alps Advisors Inc. lifted its stake in shares of Zynerba Pharmaceuticals by 41.3% in the second quarter. Alps Advisors Inc. now owns 51,375 shares of the company’s stock worth $504,000 after buying an additional 15,019 shares in the last quarter. LMR Partners LLP bought a new position in shares of Zynerba Pharmaceuticals in the second quarter worth approximately $312,000. Engineers Gate Manager LP purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $231,000. Finally, Raymond James & Associates purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $164,000. Hedge funds and other institutional investors own 16.50% of the company’s stock.

NASDAQ:ZYNE traded down $0.22 during mid-day trading on Monday, hitting $4.69. 2,520 shares of the company’s stock were exchanged, compared to its average volume of 266,310. Zynerba Pharmaceuticals has a one year low of $4.50 and a one year high of $14.45. The firm has a market capitalization of $86.55 million, a P/E ratio of -1.87 and a beta of 4.46.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Featured Story: How does a reverse stock split work?

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply